Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer-Reference-Cited by-同舟云学术

Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)–targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer

Published:2024-06 Issue: Volume:185 Page:186-193
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Richardson Debra L.,Moore Kathleen N.,Vergote Ignace,Gilbert Lucy,Martin Lainie P.,Mantia-Smaldone Gina M.,Castro Cesar M.,Provencher Diane,Matulonis Ursula A.,Stec James,Wang Yuemei,Method Michael,O'Malley David M.

Funder

ImmunoGen

Publisher

Elsevier BV

Reference36 articles.

1. Treatment of epithelial ovarian cancer;Kuroki;BMJ.,2020

2. Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment;Chien;Front. Oncol.,2013

3. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial;Parmar;Lancet.,2003

4. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an Intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG;Pfisterer;J. Clin. Oncol.,2006

5. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse;Pujade-Lauraine;J. Clin. Oncol.,2010

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and safety of anlotinib as maintenance therapy in patients with advanced non-small cell lung cancer achieving SD post first-line chemotherapy combined with immunotherapy;Journal of Chemotherapy;2024-09

2. Poly (ADP-ribose) polymerase inhibitor therapy and mechanisms of resistance in epithelial ovarian cancer;Frontiers in Oncology;2024-07-29

3. Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer;Nature Reviews Clinical Oncology;2024-03-25